Excluded studies

Excluded studies

Study reference

Reason for exclusion

Charehbili A, van de Ven S, Smit VT et al. (2014) Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Annals of oncology: official journal of the European Society for Medical Oncology 25(5), 998–1004

Does not report recurrence or survival

Fasching PA, Jud SM, Hauschild M et al. (2014) FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer 14, 66

Does not report recurrence or survival, and was terminated early

Gralow J, Barlow WE, Paterson AHG et al. (2014) SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient-stated preference for oral versus intravenous delivery. Journal of clinical oncology 32(15 suppl. 1)

Conference abstract only

Hasegawa Y, Tanino H, Horiguchi J et al. (2015) Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE Study). PLoS ONE 10(12), e0143643

Does not report recurrence or survival

Wong MHF, Stockler MR and Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD003474. DOI: 10.1002/14651858.CD003474.pub3

Meta-analysis superseded by the 2015 EBCTCG meta-analysis of individual patient data